bioRxiv Preprint: SMART-NeuroDx Unveils Reagent-Free, Machine-Learning Biosensor Platform for Point-of-Care Dementia Screening

August 2, 2026

bioRxiv International

Overview

A preprint on bioRxiv introduces SMART-NeuroDx, a reagent-free, multianalyte biosensor platform featuring a machine-learning readout for point-of-care dementia screening. The platform utilizes a four-channel PCB-based sensor array functionalized with synthetic receptor matrices to selectively target a comprehensive panel of neurological biomarkers like pTau217, GFAP, pTau181, and NfL in plasma and serum. This innovation holds significant promise for enabling earlier and more accessible dementia diagnosis.

In Depth

Key Findings

A groundbreaking research preprint published on bioRxiv introduces the SMART-NeuroDx, a novel reagent-free, multianalyte biosensor platform equipped with a machine-learning readout, specifically designed for point-of-care (POCT) dementia screening. This system promises to revolutionize early and accessible diagnosis of dementia by providing a rapid, non-invasive, and cost-effective method for biomarker detection.

Technical / Clinical Details

The SMART-NeuroDx platform is built around a four-channel printed circuit board (PCB)-based sensor array. Each channel is functionalized with a unique synthetic receptor matrix engineered to selectively capture and detect a comprehensive panel of key neurological biomarkers. These biomarkers include phosphorylated tau 217 (pTau217), glial fibrillary acidic protein (GFAP), phosphorylated tau 181 (pTau181), and neurofilament light chain (NfL), all of which are crucial indicators for Alzheimer’s disease and other neurodegenerative conditions. The distinctive feature of SMART-NeuroDx is its ‘reagent-free’ operation, which eliminates the need for costly and cumbersome reagents typically required for immunoassays. The electrical signals generated by the sensor array upon biomarker binding are then processed and interpreted by sophisticated machine-learning algorithms. This allows for the integration of multiple biomarker signals, providing a more robust and nuanced assessment of dementia risk and type directly from plasma and serum samples. The selective detection capabilities ensure high accuracy even in complex biological matrices, positioning it as a powerful diagnostic tool for primary care settings.

Background & Context

Dementia, with its rapidly increasing global prevalence, represents a critical public health challenge. Early and accurate diagnosis is paramount for effective intervention and potentially slowing disease progression. However, current diagnostic methods often involve expensive and invasive procedures such as brain imaging (PET, MRI) and cerebrospinal fluid (CSF) analysis, limiting access and increasing patient burden. Blood-based biomarkers offer a highly attractive, less invasive alternative for screening, but the challenge has been developing POCT solutions that can detect multiple biomarkers simultaneously with sufficient sensitivity and specificity. SMART-NeuroDx addresses this unmet need by combining advanced biosensing with AI, aligning with global trends in digital health and personalized diagnostics aiming for more equitable access to healthcare.

Strategic Significance & Outlook

The SMART-NeuroDx platform has the potential to profoundly transform dementia screening paradigms. Its reagent-free and POCT capabilities mean it can be readily deployed in remote areas, primary care clinics, and even home settings, dramatically improving diagnostic accessibility. Future research will focus on validating the platform in larger clinical cohorts, assessing its ability to differentiate between various types of dementia (e.g., Alzheimer’s, vascular dementia), and further optimizing sensor stability and reproducibility. If commercialized, this technology could play a vital role in facilitating earlier intervention strategies, enhancing the quality of life for patients and their families worldwide, and significantly reducing the diagnostic bottleneck in neurodegenerative disease management. The integration of machine learning further paves the way for increasingly intelligent and autonomous diagnostic systems.

Source: https://www.biorxiv.org/content/10.64898/2026.07.22.740043v1.full.pdf

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.